{
    "nctId": "NCT01702558",
    "briefTitle": "A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)",
    "officialTitle": "Phase I Study of the Combination of Trastuzumab Emtansine (T-DM1) and Capecitabine in HER2-Positive Metastatic Breast Cancer and HER2-Positive Locally Advanced/Metastatic Gastric Cancer Patients, Followed by a Randomized, Open-Label Phase II Study of Trastuzumab Emtansine and Capecitabine Versus Trastuzumab Emtansine Alone in HER2-Positive Metastatic Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer, Gastric Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 182,
    "primaryOutcomeMeasure": "Phase 1 (mBC): Percentage of Participants With Dose-Limiting Toxicities (DLTs)",
    "eligibilityCriteria": "Inclusion Criteria:\n\nMetastatic Breast Cancer\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2\n* Adequate blood cell count\n* Adequate liver, renal, and cardiac function\n* Life expectancy greater than or equal to (\\>/=) 12 weeks\n* Histologically or cytologically confirmed breast cancer\n* Confirmed HER2-positive disease, defined as immunohistochemistry (IHC) 3+ or in situ hybridization (ISH)-positive\n* mBC with at least one measurable lesion according to RECIST v1.1\n* Disease progression on at least one prior regimen containing trastuzumab and chemotherapy either separately or in combination; participants may be eligible to receive study therapy in first-line setting if trastuzumab and chemotherapy were given in the neoadjuvant/adjuvant setting\n* Participant must have recovered from previous treatments\n\nLocally Advanced/Metastatic Gastric Cancer\n\n* ECOG performance status of 0, 1, or 2\n* Adequate blood cell count\n* Adequate liver, renal, and cardiac function\n* Life expectancy \\>/= 12 weeks\n* Histologically or cytologically confirmed LA/mGC\n* HER2-positive tumor (primary tumor or metastatic lesion), defined as either IHC 3+ or IHC 2+ and ISH-positive\n* Inoperable LA/mGC\n\nExclusion Criteria:\n\nMetastatic Breast Cancer\n\n* Prior treatments before first study treatment:\n\n  1. Investigational therapy within 28 days or 5 half-lives, whichever is longer\n  2. Hormonal therapy within 14 days\n  3. Trastuzumab within 21 days\n* Prior treatment with trastuzumab emtansine or prior enrollment in a trastuzumab emtansine-containing study, regardless of whether the patient received trastuzumab emtansine\n* Prior treatment with capecitabine\n* History of severe or unexpected reactions to fluoropyrimidine or known hypersensitivity to fluorouracil\n* Related capecitabine contraindications\n\n  1. Treatment with sorivudine or chemically-related analogues\n  2. Rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption\n  3. Complete absence of dihydropyrimidine dehydrogenase (DPD) activity\n* History of intolerance or hypersensitivity to trastuzumab or murine proteins or any product component\n* History of exposure to high cumulative doses of anthracyclines\n* Brain metastases that are symptomatic or require radiation, surgery, or steroid therapy to control symptoms within 28 days before study drug\n* Current peripheral neuropathy of Grade \\>/=3\n* History of other malignancy within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or other cancers with a similar outcome\n* Current unstable ventricular arrhythmia requiring treatment\n* History of symptomatic congestive heart failure (CHF)\n* History of myocardial infarction or unstable angina within 6 months prior to study drug\n* History of left ventricular ejection fraction (LVEF) less than (\\<) 40% or symptomatic CHF with previous trastuzumab treatment\n* Severe dyspnea at rest due to complications of advanced malignancy or currently requiring continuous oxygen therapy\n* Clinically significant malabsorption syndrome or inability to take oral medication\n* Current severe, uncontrolled systemic disease (such as clinically significant cardiovascular, pulmonary, or metabolic disease)\n* Major surgical procedure or significant traumatic injury within 28 days before enrollment or anticipation of the need for major surgery during study treatment\n* Current known active infection with human immunodeficiency virus (HIV) or hepatitis B or C\n* Lapatinib within 14 days before study drug\n\nLocally Advanced/Metastatic Gastric Cancer\n\n* Same as above, with addition of previous chemotherapy for advanced/metastatic disease (prior adjuvant/neoadjuvant therapy is allowed if at least 6 months has elapsed between completion of adjuvant/neoadjuvant therapy and enrollment into the study)",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}